* no method of contact * major neurocognitive disorder, as defined by a score \<17 on the montreal cognitive assessment (moca) * history of pre-covid-19 neurologic disease (e.g., stroke) * history of severe head injury (as defined by loss of consciousness \>30 minutes) * ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 \[mini\] or alcohol use disorders test-consumption \[audit-c\] \>8) * unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and * contraindication for mri (e.g., metallic/electronic implants). * not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment

* no method of contact * major neurocognitive disorder, as defined by a score \<17 on the montreal cognitive assessment (moca) * history of pre-covid-19 neurologic disease (e.g., stroke) * history of severe head injury (as defined by loss of consciousness \>30 minutes) * ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 \[mini\] or alcohol use disorders test-consumption \[audit-c\] \>8) * unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and * contraindication for mri (e.g., metallic/electronic implants). * not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants). not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants). not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants). not involved in cognitive rehabiliation/training or daily meditative practices during study enrollment

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants). not involved in cognitive rehabiliation/training or daily meditative practices during study enrollment

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants).

no method of contact major neurocognitive disorder, as defined by a score <17 on the montreal cognitive assessment (moca) history of pre-covid-19 neurologic disease (e.g., stroke) history of severe head injury (as defined by loss of consciousness >30 minutes) ongoing substance use disorder (mini international neuropsychiatric interview version 7.0.2 [mini] or alcohol use disorders test-consumption [audit-c] >8) unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and contraindication for mri (e.g., metallic/electronic implants).